• Support
  • Contact Us
  • Corporate website
  • Customer Care
  • Training

  • ScienceWatch Home
  • Inside This Month...
  • Interviews

Featured Interviews
Author Commentaries
Institutional Interviews
Journal Interviews
Podcasts

  • Analyses

Featured Analyses
What's Hot In...
Special Topics

  • Data & Rankings

Sci-Bytes
Fast Breaking Papers
New Hot Papers
Emerging Research Fronts
Fast Moving Fronts
Corporate Research Fronts
Research Front Maps
Current Classics
Top Topics
Rising Stars
New Entrants
Country Profiles

  • About Science Watch

Methodology
Archives
Contact Us
RSS Feeds

 ScienceWatch

2008 : April 2008 - Fast Breaking Papers : Amin Rostami-Hodjegan

FAST BREAKING PAPERS - 2008

April 2008

Amin Rostami-Hodjegan talks with ScienceWatch.com and answers a few questions about this month's Fast Breaking Paper in the field of Pharmacology & Toxicology.
Rostami-Hodjegan Article Title: Simulation and prediction of in vivo drug metabolism in human populations from in vitro data
Authors: Rostami-Hodjegan, A;Tucker, GT
Journal: NAT REV DRUG DISCOV
Volume: 6
Issue: 2
Page: 140-148
Year: FEB 2007
* Royal Hallamshire Hosp, Acad Unit Clin Pharmacol, Sheffield S10 2JF, S Yorkshire, England.
* Simcyp Ltd, Blades Enterprise Ctr, Sheffield S2 4SU, S Yorkshire, England.

 Why do you think your paper is highly cited?

Since it is addressing a current issue and describes a method used to maximize the use and interpretation of data from routine in vitro studies carried out in industry. In summary, it has practical applications.

 Does it describe a new discovery, methodology, or synthesis of knowledge?

"Predictive tools for behavior of drugs once in the human body exist."

It describes a new methodology that involves integration of knowledge from different areas.

 Would you summarize the significance of your paper in layman’s terms?

Predictive tools for behavior of drugs once in the human body exist. However, most of them try to link the data to an average response and behavior. Our method discusses a change in strategy that involves prediction in population of patients (virtually) as opposed to a single non-existing average person.

 How did you become involved in this research, and were there any problems along the way?

This has been the summary of over 20 years of research to integrate different pieces of information and provide a platform to carry out the extrapolation from in vitro studies to in vivo observations.

 Where do you see your research leading in the future?

We would like to see widespread use of the technique in drug development. Currently nine out of the top ten pharmaceutical companies—based on R&D expenditure—have adapted our method. We hope this will go further and include many smaller pharma as well.

 Do you foresee any social or political implications for your research?

Yes, regulatory agencies that are the authority in accepting or rejecting applications for new drugs should include more of the typical modelling and simulation techniques which we have outlined in our report. Their collaboration in providing validation and justification of the methods is essential and should be encouraged and financially supported by the various governments. They need to maintain their assessment methods (and knowledge) up-to-date.

Amin Rostami-Hodjegan, Ph.D., Diploma in Med. Ed. FCP
Professor of Systems Pharmacology
School of Medicine
The University of Sheffield
Sheffield, South Yorkshire, UK
&
Director of Scientific Development
Simcyp Limited Blades Enterprise Centre
The Royal Hallamshire Hospital
The University of Sheffield
Sheffield, South Yorkshire, UK

back to top


2008 : April 2008 - Fast Breaking Papers : Amin Rostami-Hodjegan

  • © 2020 Clarivate
  • Careers
  • Copyright
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
Follow us Share to Twitter Share to LinkedIn Share to Facebook Share to Instagram
Previous
left arrow key
Next
right arrow key
Close Move